Recent developments include multiple analyst recommendations maintaining positive outlooks, the company outlining strategic priorities for 2026, and successful Phase 3 trial results for its HAE treatment candidate.

• RBC Capital initiated coverage of Pharvaris N.V. with an Outperform recommendation in March 2026 [N2].
• Pharvaris outlined its strategic priorities for 2026 in January 2026 [N3].
• Multiple firms including B of A Securities, Guggenheim, Morgan Stanley, and Oppenheimer maintained neutral to buy or outperform recommendations in December 2025 [N4, N5, N6, N7].
• Pharvaris’ Phase 3 trial of deucrictibant for on-demand treatment of hereditary angioedema attacks met key goals as reported in December 2025 [N4].
• General Atlantic made a $68 million investment signal in Pharvaris in late 2025 [N4].
• Discussions in early 2026 highlighted potential for significant share price rallies based on analyst expectations [N1].

Pharvaris has demonstrated clinical progress with its Phase 3 trial of deucrictibant meeting key goals, indicating potential for regulatory advancement and commercialization in the rare disease market. The company’s strong cash position supports continued development and strategic initiatives outlined for 2026. Multiple analyst firms have initiated or maintained positive coverage, reflecting confidence in the company’s pipeline and market opportunity. Investment interest from firms like General Atlantic signals external validation of Pharvaris’ prospects. The company’s focus on rare diseases with unmet needs offers potential for differentiated therapies and market penetration.

Pharvaris operates in a high-risk biopharmaceutical environment characterized by significant net losses and ongoing need for capital to fund research and development. The company’s reliance on successful clinical trial outcomes and regulatory approvals introduces execution risk. Potential future funding requirements may not be available on favorable terms, which could impact the ability to sustain development programs. Market competition, regulatory challenges, and uncertainties in commercialization of novel therapies pose risks. Currency exposure and operational costs add to financial risks. The company’s limited operating history and absence of commercial products increase business model uncertainty.

Pharvaris’ moat is primarily based on its focus on rare diseases with significant unmet medical needs, particularly hereditary angioedema and bradykinin-mediated conditions. The company’s development of innovative therapies, including deucrictibant, supported by successful late-stage clinical trials, positions it in a niche market with limited competition. Intellectual property rights and exclusive licenses underpin its product pipeline. The company’s specialized expertise, clinical development progress, and strategic partnerships contribute to barriers to entry for competitors in this rare disease segment.

• Clinical and Regulatory Risk: Pharvaris’ success depends on the outcomes of clinical trials and obtaining regulatory approvals for its product candidates, which are inherently uncertain and may delay or prevent commercialization.
• Funding and Liquidity Risk: Despite a strong cash position as of December 31, 2025, the company may require additional funding in the future, which may not be available on acceptable terms, potentially impacting research and development activities.
• Market and Commercialization Risk: The company faces risks related to market acceptance, competition, and the ability to successfully commercialize therapies for rare diseases.
• Currency and Financial Risk: Exposure to foreign exchange fluctuations, particularly USD and Swiss Franc, may affect financial results. The company manages these risks but remains vulnerable to market volatility.

• Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases, initially targeting angioedema and other bradykinin-mediated diseases [S1].
• The company’s ordinary shares have traded on the Nasdaq Global Select Market under the ticker PHVS since February 5, 2021 [S1].
• Pharvaris has several subsidiaries including Pharvaris Holdings B.V., Pharvaris Netherlands B.V., Pharvaris, Inc. (US), Pharvaris GmbH (Switzerland), and Pharvaris Pharmaceuticals, Inc. (US) [S1].
• The company’s consolidated financial statements are prepared under IFRS and presented in euros [S1].
• As of December 31, 2025, Pharvaris reported cash and cash equivalents of approximately €291.7 million [S1].
• The company reported a net loss of €175.7 million for the fiscal year ended December 31, 2025, with basic and diluted loss per share of €2.97 [S1].
• Pharvaris reclassified approximately €4.6 million from General and Administrative expenses to Research and Development expenses for 2025, with no impact on total operating expenses or net loss [S1].
• Management assessed the company’s ability to fund operations for at least 12 months after signing the financial statements and did not identify significant going concern risks, based on existing funding and cash position [S1].
• Pharvaris has contractual obligations including accrued liabilities totaling approximately €23.3 million as of December 31, 2025, related to consulting, clinical, manufacturing, nonclinical, personnel, and other accrued expenses [S1].
• The company’s financial risk management includes exposure to currency risk primarily related to USD and Swiss Franc, with proceeds from financings in USD and cash held in multiple currencies [S1].
• Pharvaris has an Equity Incentive Plan and a 2021 long-term incentive plan to attract and retain key personnel [S1].
• Recent news and analyst coverage include multiple buy, outperform, overweight, and neutral recommendations from firms such as RBC Capital, Guggenheim, Morgan Stanley, Oppenheimer, B of A Securities, and HC Wainwright [N2, N4, N5, N6, N7].
• Pharvaris outlined its 2026 strategic priorities publicly in January 2026 [N3].
• The company’s Phase 3 trial of deucrictibant for on-demand treatment of hereditary angioedema (HAE) attacks met key goals, reported in December 2025 [N4].
• Pharvaris has attracted significant investment interest, including a $68 million signal from General Atlantic in late 2025 [N4].
• The company’s shares have been discussed in the context of potential rallies and analyst expectations in early 2026 [N1].